Assessing the assessment

A scoping review of the mode of patient-reported outcome assessment in solid cancer clinical trials

Bibliographic Data

ID15296221
AuthorsN J Hubel (0009-0003-5501-1583, Innsbruck Medical University), Niclas Hubel, Daniela Krepper (0009-0009-0026-9548, Innsbruck Medical University), Lotte van der Weijst (0000-0001-8658-1894, European Organisation for Research and Treatment of Cancer), Abigirl Machingura (0000-0003-0289-9614, European Organisation for Research and Treatment of Cancer), Claudia Seidl (Innsbruck Medical University), Samuel Vorbach (0009-0003-1711-1604, Innsbruck Medical University), Samuel M Vorbach, Michelle Veil (Innsbruck Medical University), Johannes M Giesinger (0000-0003-2744-5950, Innsbruck Medical University), Monika Sztankay (0000-0002-7938-1250, Innsbruck Medical University), Scottie Kern (Critical Path Institute), Deborah Fitzsimmons (0000-0002-7286-8410, Swansea University), Dagmara Kuliś (0000-0002-2289-2113, European Organisation for Research and Treatment of Cancer), Madeline Pe (0009-0005-2531-0050, European Organisation for Research and Treatment of Cancer), Bernhard Holzner (0000-0002-3389-3621, Innsbruck Medical University), Jens Lehmann (0000-0001-6580-6644, Innsbruck Medical University, corresponding author)
Year2026
Volume35
Issue4
Publication date2026-03-01
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueQuality of Life Research (JOURNAL)
Journal identifiersISSN: 0962-9343 • E-ISSN: 1573-2649
PublisherSpringer Science+Business Media (PUBLISHER • DE)
DOI10.1007/s11136-026-04179-y
PMID41764668
OpenAlexW7133129314
LanguageEN
References cited36

Despite clear guidelines, reporting of the mode of PRO assessment remains inadequate, and active review of PRO data is uncommon. Strengthening transparency and using PROs more actively within trials could enhance patient-centered cancer research

Cancer · Clinical trial · MEDLINE · Outcome (game theory · Public health · Quality of life (healthcare · Quality of Life Research · Transparency (behavior · Cancer survivorship and care · Cancer Treatment and Pharmacology · Economic and Financial Impacts of Cancer